Arrakis Therapeutics is a preclinical-stage biopharmaceutical company developing small-molecule drugs that directly bind to and modify the biological function of RNA to treat a wide array of diseases. Arrakis is pioneering the discovery of a new class of medicines called RNA-targeted small molecules, or rSMs. Arrakis’ proprietary platform enables the identification of structures and pockets within an RNA, finds drug-like compounds that bind these pockets, evaluates the biological impact of binding, and optimizes drug candidates. Arrakis was founded in 2015 and headquartered in Waltham, MA.